Literature DB >> 10027837

S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.

M J Millan1, M Brocco, A Gobert, R Schreiber, A Dekeyne.   

Abstract

S-16924 is a potential antipsychotic that displays agonist and antagonist properties at serotonin (5-HT)1A and 5-HT2A/2C receptors, respectively. In a pigeon conflict procedure, the benzodiazepine clorazepate (CLZ) increased punished responses, an action mimicked by S-16924, whereas the atypical antipsychotic clozapine and the neuroleptic haloperidol were inactive. Similarly, in a Vogel conflict paradigm in rats, CLZ increased punished responses, an action shared by S-16924 but not by clozapine or haloperidol. This action of S-16924 was abolished by the 5-HT1A antagonist WAY-100,635. Ultrasonic vocalizations in rats were inhibited by CLZ, S-16924, clozapine, and haloperidol. However, although WAY-100,635 abolished the action of S-16924, it did not affect clozapine and haloperidol. In a rat elevated plus-maze, CLZ, but not S-16924, clozapine, and haloperidol, increased open-arm entries. Like CLZ, S-16924 increased social interaction in rats, whereas clozapine and haloperidol were inactive. WAY-100,635 abolished this action of S-16924. CLZ, S-16924, clozapine, and haloperidol decreased aggressive interactions in isolated mice, but this effect of S-16924 was not blocked by WAY-100, 635. All drugs inhibited motor behavior, but the separation to anxiolytic doses was more pronounced for S-16924 than for CLZ. Finally, in freely moving rats, CLZ and S-16924, but not clozapine and haloperidol, decreased dialysis levels of 5-HT in the nucleus accumbens: this action of S-16924 was blocked by WAY-100,165. In conclusion, in contrast to haloperidol and clozapine, S-16924 possessed a broad-based profile of anxiolytic activity at doses lower than those provoking motor disruption. Its principal mechanism of action was activation of 5-HT1A (auto)receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027837

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Modulation of mPer1 gene expression by anxiolytic drugs in mouse cerebellum.

Authors:  M Akiyama; T Kirihara; S Takahashi; Y Minami; Y Yoshinobu; T Moriya; S Shibata
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

3.  Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment.

Authors:  Silke Harich; Gerhard Gross; Anton Bespalov
Journal:  Psychopharmacology (Berl)       Date:  2007-02-23       Impact factor: 4.415

4.  CRF-5-HT interactions in the dorsal raphe nucleus and motivation for stress-induced opioid reinstatement.

Authors:  Chen Li; Nicholas McCloskey; Jared Phillips; Steven J Simmons; Lynn G Kirby
Journal:  Psychopharmacology (Berl)       Date:  2020-11-24       Impact factor: 4.415

Review 5.  Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease.

Authors:  Nicola Simola
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.